Cargando…
Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141749/ https://www.ncbi.nlm.nih.gov/pubmed/30254608 http://dx.doi.org/10.3389/fendo.2018.00525 |
_version_ | 1783355763698171904 |
---|---|
author | Casaburi, Ivan Chimento, Adele De Luca, Arianna Nocito, Marta Sculco, Sara Avena, Paola Trotta, Francesca Rago, Vittoria Sirianni, Rosa Pezzi, Vincenzo |
author_facet | Casaburi, Ivan Chimento, Adele De Luca, Arianna Nocito, Marta Sculco, Sara Avena, Paola Trotta, Francesca Rago, Vittoria Sirianni, Rosa Pezzi, Vincenzo |
author_sort | Casaburi, Ivan |
collection | PubMed |
description | The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased. |
format | Online Article Text |
id | pubmed-6141749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61417492018-09-25 Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment Casaburi, Ivan Chimento, Adele De Luca, Arianna Nocito, Marta Sculco, Sara Avena, Paola Trotta, Francesca Rago, Vittoria Sirianni, Rosa Pezzi, Vincenzo Front Endocrinol (Lausanne) Endocrinology The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased. Frontiers Media S.A. 2018-09-11 /pmc/articles/PMC6141749/ /pubmed/30254608 http://dx.doi.org/10.3389/fendo.2018.00525 Text en Copyright © 2018 Casaburi, Chimento, De Luca, Nocito, Sculco, Avena, Trotta, Rago, Sirianni and Pezzi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Casaburi, Ivan Chimento, Adele De Luca, Arianna Nocito, Marta Sculco, Sara Avena, Paola Trotta, Francesca Rago, Vittoria Sirianni, Rosa Pezzi, Vincenzo Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title_full | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title_fullStr | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title_full_unstemmed | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title_short | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
title_sort | cholesterol as an endogenous errα agonist: a new perspective to cancer treatment |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141749/ https://www.ncbi.nlm.nih.gov/pubmed/30254608 http://dx.doi.org/10.3389/fendo.2018.00525 |
work_keys_str_mv | AT casaburiivan cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT chimentoadele cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT delucaarianna cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT nocitomarta cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT sculcosara cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT avenapaola cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT trottafrancesca cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT ragovittoria cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT siriannirosa cholesterolasanendogenouserraagonistanewperspectivetocancertreatment AT pezzivincenzo cholesterolasanendogenouserraagonistanewperspectivetocancertreatment |